Meeting
2019 Gastrointestinal Cancers Symposium
Safety and efficacy of dasatinib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: A single arm, multicenters, phase 2 trial.
Authors
Jian Li
Peking University Cancer Hospital, Beijing, China
Jian Li , Ye Zhou , Xinhua Zhang , Xiaojun WU , Yongjian Zhou , Xiufeng Liu , Bo Zhang , Xin Wu , Shen Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02776878
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 138)
DOI
10.1200/JCO.2019.37.4_suppl.138
Abstract #
138
Poster Bd #
L10
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A retrospective natural history study of patients (pts) with PDGFRα D842V mutant advanced gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI).
First Author: Margaret von Mehren
Poster
2020 ASCO Virtual Scientific Program
LENVAGIST - A multicenter, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib.
First Author: Axel Le Cesne
Poster
2018 ASCO Annual Meeting
Phase II trial of continuous dosing of regorafenib in patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs) after failure of imatinib and sunitinib.
First Author: Yoon-Koo Kang
Poster
2015 Gastrointestinal Cancers Symposium
Efficacy and safety of regorafenib in Korean patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib: A multicenter study based on the management access program.
First Author: Myoung Kyun Son